Arcus Biosciences (RCUS) investor relations material

Company Overview and Strategy

• Focuses on late-stage oncology and emerging immunology programs, leveraging strong chemistry and discovery capabilities.

• Maintains aggressive research and clinical trial activity, supported by strategic partnerships and a strong cash position extending into 2H 2028.

• Portfolio includes homegrown, best-in-class small molecules, with casdatifan as the lead asset.

• Expansion into immunology is a natural evolution, not a pivot, building on existing expertise.

• Collaboration strategy now emphasizes value-adding clinical partnerships over capital-raising deals, with partners including AstraZeneca, Taiho Pharma, and Gilead.

Casdatifan Program and Market Opportunity

• Casdatifan targets HIF-2α, a validated mechanism in kidney cancer, and is wholly owned, providing strategic flexibility.

• Demonstrates superior efficacy and durability over Merck’s belzutifan, with median PFS of 12.2 months versus 5.6 months.

• Two-pronged development: PEAK-1 (fast-to-market, combo with TKI) and front-line, TKI-sparing regimens, with a Phase 3 study planned by year-end 2026.

• Large commercial potential estimated at $5 billion, driven by long treatment durations and broad applicability in clear cell RCC.

• Plans to fully cover clear cell RCC before expanding to other indications like HCC.

Other Oncology and Immunology Programs

• Quemliclustat in front-line pancreatic cancer shows median OS improvement of 5.9 months, with PRISM-1 trial fully enrolled and Phase 3 readout expected in 1H 2027.

• Immunology pipeline includes MRGPRX2 antagonist for atopic skin diseases and selective TNFR1 inhibitor, both aiming for clinical entry by 2026–2027.

• Immunology targets are validated by existing biologics but offer improved profiles via small molecules.

• Additional programs in CCR6 and CD40L are in advanced discovery stages.

• Early proof-of-concept data expected quickly for immunology assets, with large commercial opportunities.